Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Diamant Thaçi, Mette Deleuran, Andrew Blauvelt, Robert Bissonnette, Marjolein de Bruin-Weller, Michihiro Hide, Lawrence Sher, Iftikhar Hussain, Zhen Chen, Faisal A. Khokhar, Bethany Beazley, Marcella Ruddy, Naimish Patel, Neil M.H. Graham, Marius Ardeleanu, Brad Shumel*
Dive into the research topics of 'Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis'. Together they form a unique fingerprint.